Neutrophil–lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera

Kwon, Seong Soon; Yoon, Seug Yun; Jeong, Sun Young; Lee, Min Young; Kim, Kyoung-Ha; Lee, Nam-Su; Won, Jong-Ho

doi:10.1016/j.numecd.2022.04.013

Cited by 16 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned previously, MPNs are inflammatory cancers in which a malignant clone triggers the production of inflammatory cytokines. In this regard, an increase in NLR was predicted in patients with MPNs, as shown in several studies [17,18]. Some studies have reported poor prognosis in the group with a higher NLR in patients with MPN [17,19].…”

Section: Current Treatment Strategies For Patients With Pv/etmentioning

confidence: 66%

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera

Yoon

Won

2023

Blood Res

Self Cite

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells; these include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPNs are inflammatory cancers, wherein the malignant clone generates cytokines that sustain the inflammatory drive in a self-perpetuating vicious cycle. The course of MPNs follows a biological continuum, that is, from early cancer stages (ET/PV) to advanced myelofibrosis as well as impending leukemic transformation. MPN-related symptoms, e.g., fatigue, general weakness, and itching, are caused by inflammatory cytokines. Thrombosis and bleeding are also exacerbated by inflammatory cytokines in patients with MPN. Until recently, the primary objective of ET and PV therapy was to increase survival rates by preventing thrombosis. However, several medications have recently demonstrated the ability to modify the course of the disease; symptom relief is expected for most patients. In addition, there is increasing interest in the active treatment of patients at low risk with PV and ET. This review focuses on the ET/PV treatment strategies as well as novel treatment options for clinical development.

show abstract

Section: Current Treatment Strategies For Patients With Pv/etmentioning

confidence: 66%

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera

Yoon

Won

2023

Blood Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a previous study, we showed that NLR in the essential thrombocythemia and PV group was higher than that in the healthy control group (4.77 ± 3.96 vs 1.93 ± 1.03, p < 0.001). 8 In another study, NLR was significantly higher in patients with myelofibrosis than in healthy controls.…”

Section: Discussionmentioning

confidence: 91%

“…7 In a previous study, we confirmed that NLR in patients with MPN was higher than that in the normal population. 8 Although NLR & PLR are being studied as a useful predictive marker in many other diseases, very little is known about its relevance in MPN, especially in relation to diagnosis. 9 Therefore, we evaluated whether NLR & PLR could serve as a diagnostic marker for PV in patients with erythrocytosis.…”

mentioning

confidence: 99%

Neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as new possible minor criteria for diagnosis of polycythemia vera

Kim

Kwon

et al. 2023

Int J Lab Hematology

Self Cite

View full text Add to dashboard Cite

IntroductionThe role of inflammation in the pathophysiology of polycythemia vera (PV) is important. The presence of JAK2 mutations is important in the diagnosis of PV, and serum levels of erythropoietin (EPO) also play a supporting role. However, serum EPO levels show some limitations. The neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are a readily available marker of inflammation. Thus, we examined whether NLR & PLR might diagnose PV in erythrocytosis patients. We compared NLR & PLR and EPO diagnostic values.MethodsWe retrospectively reviewed clinical and laboratory data from two referral hospitals. Two hundred and eighty‐five patients with erythrocytosis who underwent a test for the JAK2 mutation were included. It wac classified as the PV group and the secondary polycythemia (SP) group.ResultsThe median NLR & PLR in the PV group (n = 70) was significantly higher than that in the SP group (n = 170) (NLR: 6.04 vs. 1.77, PLR: 283.18 vs. 101.56, respectively, p < 0.001). In the receiver operating characteristic analysis, the area under the curve of NLR & PLR was significantly higher than that of serum EPO (NLR vs EPO: 0.921 vs. 0.827, p = 0.003; PLR vs EPO: 0.917 vs 0.827, p = 0.003).ConclusionIn conclusion, NLR & PLR were higher in PV than in SP and showed better diagnostic value than serum EPO level, highlighting their potential as minor diagnostic criteria in patients with PV.

show abstract

“… 38 Moreover, JAK2 signaling interacts with traditional vascular risk factors, and in PV, JAK2 V617F VAF associated with a higher neutrophil to lymphocyte ratio and carotid plaque burden, and higher elevations of C-reactive protein ( Table 1 ). 36 , 53 …”

Section: Jak2 V617f and Thrombotic Risk In Pvmentioning

confidence: 99%

JAK2 V617F allele burden in polycythemia vera: burden of proof

Moliterno

Kaizer

Reeves

2023

Blood

View full text Add to dashboard Cite

Polycythemia vera (PV) is a hematopoietic stem cell (HSC) neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; significant burden of disease-specific symptoms; high rates of vascular events; and evolution to a myelofibrosis phase or acute leukemia. The JAK2V617F variant allele frequency (VAF) is a key determinant of outcomes in PV, including thrombosis and myelofibrotic progression. Herein we critically review the dynamic role of JAK2V617F mutation burden in the pathogenesis and natural history of PV, suitability of JAK2V617F VAF as a diagnostic and prognostic biomarker, and utility of JAK2V617F VAF reduction in PV treatment.

show abstract

Neutrophil–lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera

Cited by 16 publications

References 11 publications

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera

Neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as new possible minor criteria for diagnosis of polycythemia vera

JAK2 V617F allele burden in polycythemia vera: burden of proof

Contact Info

Product

Resources

About